Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis

Bibliography

• Melton LJr. Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 2003;18(6):1139-41
   PubMed Web of Science ®Google Scholar
• McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005;165(15):1762-8
   PubMed Web of Science ®Google Scholar
• Keaveny TM, Donley DW, Hoffmann PF, et al. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 2007;22(1):149-57
   PubMed Web of Science ®Google Scholar
• Murad MH, Drake MT, Mullan RJ, et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2012;97(6):1871-80
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Jorgensen NR, Schwarz P, Mosekilde L. Effects of treatment with fluoride on bone mineral density and fracture risk–a meta-analysis. Osteoporos Int 2008;19(3):257-68
   PubMed Web of Science ®Google Scholar
• Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 2008;29(5):535-59
   PubMed Web of Science ®Google Scholar
• Soper DL, Wang Y, De B, et al. The design and synthesis of selective prostaglandin analogs as bone anabolic agents for the potential treatment of osteoporosis. Adv Exp Med Biol 2002;507:303-7
   PubMed Web of Science ®Google Scholar
• Qin L, Raggatt LJ, Partridge NC. Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol Metab 2004;15(2):60-5
   PubMed Web of Science ®Google Scholar
• Nissenson RA, Juppner H. Parathyroid hormone. In: Rosen CJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism: American society for bone and mineral research. Willey-Blackwell; Ames, Iowa, USA: 2013
   Google Scholar
• Li X, Liu H, Qin L, et al. Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J Biol Chem 2007;282(45):33086-97
   PubMed Web of Science ®Google Scholar
• Juppner H, Abou-Samra AB, Freeman M, et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 1991;254(5034):1024-6
   PubMed Web of Science ®Google Scholar
• Datta NS, Abou-Samra AB. PTH and PTHrP signaling in osteoblasts. Cell Signal 2009;21(8):1245-54
   PubMed Web of Science ®Google Scholar
• Lee K, Brown D, Urena P, et al. Localization of parathyroid hormone/parathyroid hormone-related peptide receptor mRNA in kidney. Am J Physiol 1996;270(1 Pt 2):F186-91
   PubMed Web of Science ®Google Scholar
• Lee M, Partridge NC. Parathyroid hormone signaling in bone and kidney. Curr Opin Nephrol Hypertens 2009;18(4):298-302
   PubMed Web of Science ®Google Scholar
• Ferrandon S, Feinstein TN, Castro M, et al. Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. Nat Chem Biol 2009;5(10):734-42
   PubMed Web of Science ®Google Scholar
• Tawfeek HA, Qian F, Abou-Samra AB. Phosphorylation of the receptor for PTH and PTHrP is required for internalization and regulates receptor signaling. Mol Endocrinol 2002;16(1):1-13
   PubMed Web of Science ®Google Scholar
• McCudden CR, Hains MD, Kimple RJ, et al. G-protein signaling: back to the future. Cell Mol Life Sci 2005;62(5):551-77
   PubMed Web of Science ®Google Scholar
• Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002;3(9):639-50
   PubMed Web of Science ®Google Scholar
• Yang D, Singh R, Divieti P, et al. Contributions of parathyroid hormone (PTH)/PTH-related peptide receptor signaling pathways to the anabolic effect of PTH on bone. Bone 2007;40(6):1453-61
   PubMed Web of Science ®Google Scholar
• Yu S, Franceschi RT, Luo M, et al. Parathyroid hormone increases activating transcription factor 4 expression and activity in osteoblasts: requirement for osteocalcin gene expression. Endocrinology 2008;149(4):1960-8
   PubMed Web of Science ®Google Scholar
• Lee SK, Lorenzo JA. Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures. Bone 2002;31(1):252-9
   PubMed Web of Science ®Google Scholar
• Kim MS, Day CJ, Morrison NA. MCP-1 is induced by receptor activator of nuclear factor-{kappa}B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation. J Biol Chem 2005;280(16):16163-9
   PubMed Web of Science ®Google Scholar
• Liu F, Lee SK, Adams DJ, et al. CREM deficiency in mice alters the response of bone to intermittent parathyroid hormone treatment. Bone 2007;40(4):1135-43
   PubMed Web of Science ®Google Scholar
• Bellido T, Ali AA, Plotkin LI, et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 2003;278(50):50259-72
   PubMed Web of Science ®Google Scholar
• Selvamurugan N, Shimizu E, Lee M, et al. Identification and characterization of Runx2 phosphorylation sites involved in matrix metalloproteinase-13 promoter activation. FEBS Lett 2009;583(7):1141-6
   PubMed Web of Science ®Google Scholar
• Linglart A, Menguy C, Couvineau A, et al. Recurrent PRKAR1A mutation in acrodysostosis with hormone resistance. N Engl J Med 2011;364(23):2218-26
   PubMed Web of Science ®Google Scholar
• Weinstein LS, Liu J, Sakamoto A, et al. Minireview: GNAS: normal and abnormal functions. Endocrinology 2004;145(12):5459-64
   PubMed Web of Science ®Google Scholar
• Guo J, Liu M, Yang D, et al. Phospholipase C signaling via the parathyroid hormone (PTH)/PTH-related peptide receptor is essential for normal bone responses to PTH. Endocrinology 2010;151(8):3502-13
   PubMed Web of Science ®Google Scholar
• Traebert M, Volkl H, Biber J, et al. Luminal and contraluminal action of 1-34 and 3-34 PTH peptides on renal type IIa Na-P(i) cotransporter. Am J Physiol Renal Physiol 2000;278(5):F792-8
   PubMed Web of Science ®Google Scholar
• Wan M, Yang C, Li J, et al. Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev 2008;22(21):2968-79
   PubMed Web of Science ®Google Scholar
• Romero G, Sneddon WB, Yang Y, et al. Parathyroid hormone receptor directly interacts with dishevelled to regulate beta-catenin signaling and osteoclastogenesis. J Biol Chem 2010;285(19):14756-63
   PubMed Web of Science ®Google Scholar
• Taurin S, Sandbo N, Qin Y, et al. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem 2006;281(15):9971-6
   PubMed Web of Science ®Google Scholar
• Fang X, Yu SX, Lu Y, et al. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci USA 2000;97(22):11960-5
   PubMed Web of Science ®Google Scholar
• Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005;280:19883-7
   PubMed Web of Science ®Google Scholar
• Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005;146(11):4577-83
   PubMed Web of Science ®Google Scholar
• Bianchi EN, Ferrari SL. Beta-arrestin2 regulates parathyroid hormone effects on a p38 MAPK and NFkappaB gene expression network in osteoblasts. Bone 2009;45(4):716-25
   PubMed Web of Science ®Google Scholar
• Maeda A, Okazaki M, Baron DM, et al. Critical role of parathyroid hormone (PTH) receptor-1 phosphorylation in regulating acute responses to PTH. Proc Natl Acad Sci USA 2013;110(15):5864-9
   PubMed Web of Science ®Google Scholar
• Vilardaga JP, Romero G, Friedman PA, Gardella TJ. Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm. Cell Mol Life Sci 2011;68(1):1-13
   PubMed Web of Science ®Google Scholar
• Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science 2005;308(5721):512-17
   PubMed Web of Science ®Google Scholar
• Vilardaga JP, Gardella TJ, Wehbi VL, Feinstein TN. Non-canonical signaling of the PTH receptor. Trends Pharmacol Sci 2012;33(8):423-31
   PubMed Web of Science ®Google Scholar
• Wang B, Yang Y, Abou-Samra AB, Friedman PA. NHERF1 regulates parathyroid hormone receptor desensitization: interference with beta-arrestin binding. Mol Pharmacol 2009;75(5):1189-97
   PubMed Web of Science ®Google Scholar
• Syme CA, Friedman PA, Bisello A. Parathyroid hormone receptor trafficking contributes to the activation of extracellular signal-regulated kinases but is not required for regulation of cAMP signaling. J Biol Chem 2005;280(12):11281-8
   PubMed Web of Science ®Google Scholar
• Sneddon WB, Syme CA, Bisello A, et al. Activation-independent parathyroid hormone receptor internalization is regulated by NHERF1 (EBP50). J Biol Chem 2003;278(44):43787-96
   PubMed Web of Science ®Google Scholar
• Ferrari SL, Pierroz DD, Glatt V, et al. Bone response to intermittent parathyroid hormone is altered in mice null for β-Arrestin2. Endocrinology 2005;146(4):1854-62
   PubMed Web of Science ®Google Scholar
• Pierroz DD, Rufo A, Bianchi EN, et al. Beta-Arrestin2 regulates RANKL and ephrins gene expression in response to bone remodeling in mice. J Bone Miner Res 2009;24(5):775-84
   PubMed Web of Science ®Google Scholar
• Pi M, Oakley RH, Gesty-Palmer D, et al. Beta-arrestin- and G protein receptor kinase-mediated calcium-sensing receptor desensitization. Mol Endocrinol 2005;19(4):1078-87
   PubMed Web of Science ®Google Scholar
• Bohinc BN, Gesty-Palmer D. Arrestins in bone. Prog Mol Biol Transl Sci 2013;118:335-58
   PubMed Web of Science ®Google Scholar
• Ferrari SL, Bouxsein ML. Beta-arrestin-biased parathyroid hormone ligands: a new approach to the development of agents that stimulate bone formation. Sci Transl Med 2009;1(1):1ps1
   PubMedGoogle Scholar
• Gesty-Palmer D, Flannery P, Yuan L, et al. A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med 2009;1(1):1ra1
   PubMed Web of Science ®Google Scholar
• Gesty-Palmer D, Yuan L, Martin B, et al. β-arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo. Mol Endocrinol 2013;27(2):296-314
   PubMed Web of Science ®Google Scholar
• Bisello A, Chorev M, Rosenblatt M, et al. Selective ligand-induced stabilization of active and desensitized parathyroid hormone type 1 receptor conformations. J Biol Chem 2002;277(41):38524-30
   PubMed Web of Science ®Google Scholar
• Gesty-Palmer D, Chen M, Reiter E, et al. Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem 2006;281(16):10856-64
   PubMed Web of Science ®Google Scholar
• Premont RT, Gainetdinov RR. Physiological roles of G protein-coupled receptor kinases and arrestins. Annu Rev Physiol 2007;69:511-34
   PubMed Web of Science ®Google Scholar
• Lovgren AK, Kovacs JJ, Xie T, et al. β-arrestin deficiency protects against pulmonary fibrosis in mice and prevents fibroblast invasion of extracellular matrix. Sci Transl Med 2011;3(74):74ra23
   PubMedGoogle Scholar
• Rowan MP, Szteyn K, Doyle AP, et al. β-arrestin-2-biased agonism of delta opioid receptors sensitizes transient receptor potential vanilloid type 1 (TRPV1) in primary sensory neurons. Mol Pain 2014;10:50
   PubMed Web of Science ®Google Scholar
• Watari K, Nakaya M, Nishida M, Kim KM. Kurose H. beta-arrestin2 in infiltrated macrophages inhibits excessive inflammation after myocardial infarction. PLoS One 2013;8(7):e68351
   PubMed Web of Science ®Google Scholar
• Gaffal E, Jakobs M, Glodde N, et al. Beta-Arrestin 2 Inhibits Proinflammatory Chemokine Production and Attenuates Contact Allergic Inflammation in the Skin. J Invest Dermatol 2014;134(8):2131-7
   PubMed Web of Science ®Google Scholar
• Whitfield JF. The clinical prospects of the invisible PTHs. Growing Bone. 2nd edition. Landes Bioscience; Austin, Texas: 2007. p. 168-71
   Google Scholar
• Cosman F, Lane NE, Bolognese MA, et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2010;95(1):151-8
   PubMed Web of Science ®Google Scholar
• Hammerle SP, Mindeholm L, Launonen A, et al. The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. Bone 2012;50(4):965-73
   PubMed Web of Science ®Google Scholar
• Whitfield JF, Morley P, Willick GE, et al. Stimulation of the growth of femoral trabecular bone in ovariectomized rats by the novel parathyroid hormone fragment, hPTH-(1-31)NH2 (Ostabolin). Calcif Tissue Int 1996;58(2):81-7
   PubMed Web of Science ®Google Scholar
• Fraher LJ, Avram R, Watson PH, et al. Comparison of the biochemical responses to human parathyroid hormone-(1-31)NH2 and hPTH-(1-34) in healthy humans. J Clin Endocrinol Metab 1999;84(8):2739-43
   PubMed Web of Science ®Google Scholar
• Whitfield JF, Morley P, Fraher L, et al. The stimulation of vertebral and tibial bone growth by the parathyroid hormone fragments, hPTH-(1-31)NH2, [Leu27]cyclo(Glu22-Lys26)hPTH-(1-31)NH2, and hPTH-(1-30)NH2. Calcif Tissue Int 2000;66(4):307-12
   PubMed Web of Science ®Google Scholar
• Whitfield JF, Morley P, Willick GE, et al. Comparison of the abilities of human parathyroid hormone(1-31)NH2 and human parathyroid hormone-related protein(1-31)NH2 to stimulate femoral trabecular bone growth in ovariectomized rats. Calcif Tissue Int 1997;61(4):322-6
   PubMed Web of Science ®Google Scholar
• Sturmer A, Mehta N, Giacchi J, et al. Pharmacokinetics of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis. Clin Pharmacokinet 2013;52(11):995-1004
   PubMed Web of Science ®Google Scholar
• Henriksen K, Andersen JR, Riis BJ, et al. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis. Bone 2013;53(1):160-6
   PubMed Web of Science ®Google Scholar
• Whitfield JF, Morley P, Willick G, et al. Cyclization by a specific lactam increases the ability of human parathyroid hormone (hPTH)-(1-31)NH2 to stimulate bone growth in ovariectomized rats. J Bone Miner Res 1997;12(8):1246-52
   PubMed Web of Science ®Google Scholar
• Hodsman A, Bone H, Gallagher C, et al. Ostabolin-C™ increases lumbar spine and hip BMD after 1 year of therapy: results of a phase II clinical trial. 2007 29th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) Presentation 1130, Honolulu, Hawaii, USA: 2007
   Google Scholar
• Morley P, Bishop J, Anderson R, et al. Pulmonary delivery of the parathyroid hormone analogue ostabolin-C™ stimulates markers of bone formation in postmenopausal women. 2007 29th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) Presentation M421, Honolulu, Hawaii, USA: 2007
   Google Scholar
• Stewart AF, Cain RL, Burr DB, et al. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893. J Bone Miner Res 2000;15(8):1517-25
   PubMed Web of Science ®Google Scholar
• Neerup TS, Stahlhut M, Petersen JS, et al. ZP2307, a novel, cyclic PTH(1-17) analog that augments bone mass in ovariectomized rats. Bone 2011;48(6):1319-27
   PubMed Web of Science ®Google Scholar
• Feng J, Liu Y, Xing Y, et al. A novel human parathyroid hormone (1-34) analog for the treatment of osteoporosis. Peptides 2009;30(6):1173-80
   PubMed Web of Science ®Google Scholar
• Lin K, Len Y, Feng J, et al. Structure of a novel PTH-related peptide hPTH’ and its interaction with the PTH receptor. J Pept Sci 2012;18(6):413-17
   PubMed Web of Science ®Google Scholar
• Chunxiao W, Yu Z, Wentao L, et al. Impacts of the N-terminal fragment analog of human parathyroid hormone on structure, composition and biomechanics of bone. Eur J Pharm Sci 2012;47(5):926-33
   PubMed Web of Science ®Google Scholar
• Chunxiao W, Jingjing L, Yire X, et al. Study on preparation and activity of a novel recombinant human parathyroid hormone(1-34) analog with N-terminal Pro-Pro extension. Regul Pept 2007;141(1-3):35-43
   PubMed Web of Science ®Google Scholar
• Shi X, Wang C, Zhuang Z, et al. Nasal administration of a novel recombinant human parathyroid hormone (1-34) analog for the treatment of osteoporosis of ovariectomized rats. Regul Pept 2011;170(1-3):52-6
   PubMed Web of Science ®Google Scholar
• Everhart-Caye M, Inzucchi SE, Guinness-Henry J, et al. Parathyroid hormone (PTH)-related protein(1-36) is equipotent to PTH(1-34) in humans. J Clin Endocrinol Metab 1996;81(1):199-208
   PubMed Web of Science ®Google Scholar
• Strewler GJ. The physiology of parathyroid hormone-related protein. N Engl J Med 2000;342(3):177-85
   PubMed Web of Science ®Google Scholar
• Horwitz MJ, Tedesco MB, Sereika SM, et al. Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J Bone Miner Res 2005;20(10):1792-803
   PubMed Web of Science ®Google Scholar
• Horwitz MJ, Tedesco MB, Sereika SM, et al. A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover. J Bone Miner Res 2011;26(9):2287-97
   PubMed Web of Science ®Google Scholar
• Plotkin H, Gundberg C, Mitnick M, Stewart AF. Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis. J Clin Endocrinol Metab 1998;83(8):2786-91
   PubMed Web of Science ®Google Scholar
• Whitfield JF. Parathyroid Hormone-Related Protein (PTHrP): an ancient string of cytokines with many known and still unknown functions. In: Luparello C, editor. Nova Science Publishers, Inc. Novel aspects of PTHrP physiopathology; Hauppauge, New York, USA: 2007. p. 1-25
   Google Scholar
• Whitfield JF, Isaacs RJ, Chakravarthy BR, et al. C-terminal fragments of parathyroid hormone-related protein, PTHrP-(107-111) and (107-139), and the N-terminal PTHrP-(1-40) fragment stimulate membrane-associated protein kinase C activity in rat spleen lymphocytes. J Cell Physiol 1994;158(3):518-22
   PubMed Web of Science ®Google Scholar
• Horwitz MJ, Tedesco MB, Gundberg C, et al. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003;88(2):569-75
   PubMed Web of Science ®Google Scholar
• Horwitz MJ, Tedesco MB, Sereika SM, et al. Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: a dose escalation study. Osteoporos Int 2006;17(2):225-30
   PubMed Web of Science ®Google Scholar
• Horwitz MJ, Tedesco MB, Garcia-Ocana A, et al. Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J Clin Endocrinol Metab 2010;95(3):1279-87
   PubMed Web of Science ®Google Scholar
• Horwitz MJ, Augustine M, Khan L, et al. A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: the PrOP study. J Bone Miner Res 2013;28(11):2266-76
   PubMed Web of Science ®Google Scholar
• Xu J, Rong H, Ji H, et al. Effects of different dosages of parathyroid hormone-related protein 1-34 on the bone metabolism of the ovariectomized rat model of osteoporosis. Calcif Tissue Int 2013;93(3):276-87
   PubMed Web of Science ®Google Scholar
• Hattersley G BJ, Guerriero J, Kumar P, et al. Bone anabolic efficacy and safety of BA058, a novel analog of hPTHrP: 12-month extension data from a phase 2 clinical trial in postmenopausal women with osteoporosis. Bone 2013: European Calcified Tissue Society Congress Lisbon, Portugal: Bone Abstracts; 2013
   Google Scholar
• Weir EC, Terwilliger G, Sartori L, Insogna KL. Synthetic parathyroid hormone-like protein (1-74) is anabolic for bone in vivo. Calcif Tissue Int 1992;51(1):30-4
   PubMed Web of Science ®Google Scholar
• Wang H, Liu J, Yin Y, et al. Recombinant human parathyroid hormone related protein 1-34 and 1-84 and their roles in osteoporosis treatment. PLoS One 2014;9(2):e88237
   PubMedGoogle Scholar
• Pellegrini M, Bisello A, Rosenblatt M, et al. Conformational studies of RS-66271, an analog of parathyroid hormone-related protein with pronounced bone anabolic activity. J Med Chem 1997;40(19):3025-31
   PubMed Web of Science ®Google Scholar
• Vickery BH, Avnur Z, Cheng Y, et al. RS-66271, a C-terminally substituted analog of human parathyroid hormone-related protein (1-34), increases trabecular and cortical bone in ovariectomized, osteopenic rats. J Bone Miner Res 1996;11(12):1943-51
   PubMed Web of Science ®Google Scholar
• Hoare SR, Usdin TB. The discrepancy between the binding affinity of PTH (1-34) and RS 66271 is explained by interaction of the PTH/PTHrP receptor with G-protein. J Bone Miner Res 2000;15(3):605-8
   PubMed Web of Science ®Google Scholar
• Bostrom MP, Gamradt SC, Asnis P, et al. Parathyroid hormone-related protein analog RS-66271 is an effective therapy for impaired bone healing in rabbits on corticosteroid therapy. Bone 2000;26(5):437-42
   PubMed Web of Science ®Google Scholar
• de Gortazar AR, Alonso V, Alvarez-Arroyo MV, Esbrit P. Transient exposure to PTHrP (107-139) exerts anabolic effects through vascular endothelial growth factor receptor 2 in human osteoblastic cells in vitro. Calcif Tissue Int 2006;79(5):360-9
   PubMed Web of Science ®Google Scholar
• Alonso V, de Gortazar AR, Ardura JA, et al. Parathyroid hormone-related protein (107-139) increases human osteoblastic cell survival by activation of vascular endothelial growth factor receptor-2. J Cell Physiol 2008;217(3):717-27
   PubMed Web of Science ®Google Scholar
• Cuthbertson RM, Kemp BE, Barden JA. Structure study of osteostatin PTHrP[Thr107](107-139). Biochim Biophys Acta 1999;1432(1):64-72
   PubMed Web of Science ®Google Scholar
• Fenton AJ, Martin TJ, Nicholson GC. Long-term culture of disaggregated rat osteoclasts: inhibition of bone resorption and reduction of osteoclast-like cell number by calcitonin and PTHrP[107-139]. J Cell Physiol 1993;155(1):1-7
   PubMed Web of Science ®Google Scholar
• Zheng MH, McCaughan HB, Papadimitriou JM, et al. Tartrate resistant acid phosphatase activity in rat cultured osteoclasts is inhibited by a carboxyl terminal peptide (osteostatin) from parathyroid hormone-related protein. J Cell Biochem 1994;54(2):145-53
   PubMed Web of Science ®Google Scholar
• Lozano D, Manzano M, Doadrio JC, et al. Osteostatin-loaded bioceramics stimulate osteoblastic growth and differentiation. Acta Biomater 2010;6(3):797-803
   PubMed Web of Science ®Google Scholar
• Garcia-Martin A, Acitores A, Maycas M, et al. Src kinases mediate VEGFR2 transactivation by the osteostatin domain of PTHrP to modulate osteoblastic function. J Cell Biochem 2013;114(6):1404-13
   PubMed Web of Science ®Google Scholar